|
Enews from the Alzheimer's Association
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Progress seen in Alzheimer’s research in wake of disappointing trial
|
|
The Alzheimer’s Association is disappointed by the topline Phase 3 data reported by Genentech and Roche from the GRADUATE Phase 3 global clinical trials of gantenerumab. However, these results will contribute to our understanding of Alzheimer’s, and the Association is confident about the robust and diverse Alzheimer’s drug development pipeline.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pitch competition aims to increase cognitive assessment in primary care
|
|
|
The Alzheimer’s Association is partnering with MATTER, a global healthcare startup incubator, to discover innovative solutions to increase cognitive assessment and early detection and diagnosis of dementia. The Alzheimer’s Association Pitch Competition invites health care entrepreneurs, industry innovators, scientists and clinicians to submit their best ideas for increasing cognitive assessment in primary care practice.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
My Preferences:
|
Unsubscribe
To stop receiving our weekly e-newsletter, simply unsubscribe.
|
|
Subscribe
Was this e-newsletter forwarded to you? Subscribe to get it weekly.
|
|
|
|
The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.
Alzheimer's Association Home Office 225 N. Michigan Ave., Fl. 17, Chicago, IL 60601 © 2022 Alzheimer's Association. All rights reserved. www.alz.org | 800.272.3900.
|
|
|
